Page last updated: 2024-10-31

molsidomine and Impotence

molsidomine has been researched along with Impotence in 13 studies

Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS.
molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure.

Research Excerpts

ExcerptRelevanceReference
" Different studies on the performance of the direct NO donor linsidomine chlorhydrate (SIN-1) in patients with erectile dysfunction have had conflicting results."9.07Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction. ( Klän, R; Knispel, HH; Meier, T; Miller, K; Wegner, HE, 1994)
"Recently, nitric oxide was shown to be a mediator of penile erection in men and the nitric oxide donor linsidomine chlorhydrate (SIN-1) was introduced as a novel treatment option in patients with erectile dysfunction."9.07Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. ( Becker, AJ; Djamilian, MH; Jonas, U; Stief, CG; Truss, MC, 1994)
" Different studies on the performance of the direct NO-donor linsidomine chlorhydrate (SIN-1) in patients with erectile dysfunction have come to conflicting results ranging from highest praise to complete dismissal."8.79Nitric oxide donor, linsidomine chlorhydrate (SIN-1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature. ( Klän, R; Knispel, HH; Meier, T; Miller, K; Wegner, HE, 1995)
"The results highlight the rationale behind the repositioning of molsidomine therapy for the management of diabetic erectile dysfunction."7.88Repositioning of molsidomine for its efficacy in diabetes induced erectile dysfunction in rats: In silico, in vitro and in vivo approach. ( Minaz, N; Pathak, L; Razdan, R, 2018)
" Since nitric oxide seems to account for the biological actions of endothelium derived relaxing factor, a study was done to examine a possible role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the treatment of erectile dysfunction."7.68Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction. ( Andersson, KE; Djamilian, M; Holmquist, F; Jonas, U; Krah, H; Stief, CG, 1992)
"SIN-1 is not superior to PGE1 in the treatment of erectile dysfunction caused by venous leakage, and failure of NO-mediated smooth muscle relaxation does not play a part in the entity, "venous leakage."5.29Effect of nitric oxide-donor, linsidomine chlorhydrate, in treatment of human erectile dysfunction caused by venous leakage. ( Knispel, HH; Wegner, HE, 1993)
" Different studies on the performance of the direct NO donor linsidomine chlorhydrate (SIN-1) in patients with erectile dysfunction have had conflicting results."5.07Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction. ( Klän, R; Knispel, HH; Meier, T; Miller, K; Wegner, HE, 1994)
"Recently, nitric oxide was shown to be a mediator of penile erection in men and the nitric oxide donor linsidomine chlorhydrate (SIN-1) was introduced as a novel treatment option in patients with erectile dysfunction."5.07Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. ( Becker, AJ; Djamilian, MH; Jonas, U; Stief, CG; Truss, MC, 1994)
" Different studies on the performance of the direct NO-donor linsidomine chlorhydrate (SIN-1) in patients with erectile dysfunction have come to conflicting results ranging from highest praise to complete dismissal."4.79Nitric oxide donor, linsidomine chlorhydrate (SIN-1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature. ( Klän, R; Knispel, HH; Meier, T; Miller, K; Wegner, HE, 1995)
"The results highlight the rationale behind the repositioning of molsidomine therapy for the management of diabetic erectile dysfunction."3.88Repositioning of molsidomine for its efficacy in diabetes induced erectile dysfunction in rats: In silico, in vitro and in vivo approach. ( Minaz, N; Pathak, L; Razdan, R, 2018)
"Linsidomine induced complete rigidity in 4 subjects considered to suffer from psychogenic impotence (versus 11 subjects with PGE1) and 1 subject considered to suffer from arterial disease (versus 8 subjects with PGE1)."3.70[Erectile response to intracavernous injection of linsidomine in 38 impotent patients. Comparison with prostaglandin E1]. ( Buvat, J; Lemaire, A, 1998)
" Since nitric oxide seems to account for the biological actions of endothelium derived relaxing factor, a study was done to examine a possible role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the treatment of erectile dysfunction."3.68Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction. ( Andersson, KE; Djamilian, M; Holmquist, F; Jonas, U; Krah, H; Stief, CG, 1992)
"SIN-1 is not superior to PGE1 in the treatment of erectile dysfunction caused by venous leakage, and failure of NO-mediated smooth muscle relaxation does not play a part in the entity, "venous leakage."1.29Effect of nitric oxide-donor, linsidomine chlorhydrate, in treatment of human erectile dysfunction caused by venous leakage. ( Knispel, HH; Wegner, HE, 1993)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's10 (76.92)18.2507
2000's2 (15.38)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Minaz, N1
Razdan, R1
Pathak, L1
Machtens, S1
Ckert, S1
Stief, CG4
Tsikas, D1
Frlich, Jr1
Jonas, U4
Porst, H2
Wegner, HE3
Knispel, HH3
Klän, R2
Meier, T2
Miller, K2
Truss, MC2
Becker, AJ1
Djamilian, MH1
Schultheiss, D1
Lemaire, A1
Buvat, J1
Maisch, B1
Holmquist, F1
Djamilian, M1
Krah, H1
Andersson, KE1

Reviews

2 reviews available for molsidomine and Impotence

ArticleYear
Nitric oxide donor, linsidomine chlorhydrate (SIN-1), in the diagnosis and treatment of erectile dysfunction: critical appraisal and review of the literature.
    International urology and nephrology, 1995, Volume: 27, Issue:5

    Topics: Animals; Erectile Dysfunction; Humans; Male; Molsidomine; Vasodilator Agents

1995
[Pharmacological therapy in erectile dysfunction--current standards and new viewpoint].
    Wiener medizinische Wochenschrift (1946), 1997, Volume: 147, Issue:4-5

    Topics: Alprostadil; Dosage Forms; Enzyme Inhibitors; Erectile Dysfunction; Humans; Male; Molsidomine; Muscl

1997

Trials

3 trials available for molsidomine and Impotence

ArticleYear
Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction.
    Urologia internationalis, 1994, Volume: 53, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Alprostadil; Cross-Over Studies; Erectile Dysfunction; Humans; Male;

1994
Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction.
    Urology, 1994, Volume: 44, Issue:4

    Topics: Adult; Aged; Drug Therapy, Combination; Electromyography; Erectile Dysfunction; Follow-Up Studies; H

1994
Prostaglandin E1 and the nitric oxide donor linsidomine for erectile failure: a diagnostic comparative study of 40 patients.
    The Journal of urology, 1993, Volume: 149, Issue:5 Pt 2

    Topics: Adult; Aged; Alprostadil; Blood Flow Velocity; Erectile Dysfunction; Humans; Male; Middle Aged; Mols

1993

Other Studies

8 other studies available for molsidomine and Impotence

ArticleYear
Repositioning of molsidomine for its efficacy in diabetes induced erectile dysfunction in rats: In silico, in vitro and in vivo approach.
    Pharmacological reports : PR, 2018, Volume: 70, Issue:2

    Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Diabetes Mellitus, Experimental; Drug Repositioning

2018
Effects of various nitric oxide-donating drugs on adrenergic tension of human seminal vesicles in vitro.
    Urology, 2003, Volume: 61, Issue:2

    Topics: Adrenergic alpha-Agonists; Aged; Colforsin; Cyclic GMP; Ejaculation; Erectile Dysfunction; Humans; I

2003
The rationale for prostaglandin E1 (alpha-alprostadil) in the management of male impotence.
    Advances in prostaglandin, thromboxane, and leukotriene research, 1995, Volume: 23

    Topics: Alprostadil; Erectile Dysfunction; Humans; Impotence, Vasculogenic; Male; Molsidomine; Moxisylyte; P

1995
Effect of nitric oxide-donor, linsidomine chlorhydrate, in treatment of human erectile dysfunction caused by venous leakage.
    Urology, 1993, Volume: 42, Issue:4

    Topics: Adult; Aged; Alprostadil; Erectile Dysfunction; Humans; Male; Middle Aged; Molsidomine; Nitric Oxide

1993
[Erectile response to intracavernous injection of linsidomine in 38 impotent patients. Comparison with prostaglandin E1].
    Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1998, Volume: 8, Issue:3

    Topics: Adult; Aged; Alprostadil; Data Interpretation, Statistical; Erectile Dysfunction; Humans; Impotence,

1998
[Therapy recommendations for adverse effects of Viagra and nitrates (NO-donors)].
    Herz, 1998, Volume: 23, Issue:7

    Topics: Angina Pectoris; Blood Pressure; Contraindications; Drug Therapy, Combination; Erectile Dysfunction;

1998
[Erectile dysfunction. Help also for cardiac patients].
    MMW Fortschritte der Medizin, 2001, Oct-11, Volume: 143, Issue:41

    Topics: Apomorphine; Contraindications; Coronary Disease; Drug Interactions; Erectile Dysfunction; Humans; M

2001
Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction.
    The Journal of urology, 1992, Volume: 148, Issue:5

    Topics: Blood Flow Velocity; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Male; Molsidomi

1992